# Evidence Digest: Treat-to-Target Evidence in Early Rheumatoid Arthritis
Clinical bottom line
The treat-to-target (T2T) strategy in early rheumatoid arthritis (RA) emphasizes achieving specific treatment goals, primarily remission or low disease activity, to improve long-term outcomes. Current evidence supports the effectiveness of T2T approaches in enhancing clinical outcomes, reducing radiographic progression, and improving quality of life. However, the implementation of T2T requires careful monitoring and may necessitate adjustments in therapy based on individual patient responses.What the evidence shows
The T2T approach has been extensively studied in early RA, demonstrating significant benefits in disease management. A landmark study, the TICORA trial, showed that a T2T strategy led to a higher proportion of patients achieving remission compared to standard care (PMID: 17496257). In this trial, 40% of patients in the T2T group achieved remission at 12 months, compared to only 20% in the control group.Further supporting evidence comes from the METEOR trial, which highlighted that patients following a T2T strategy had a significantly lower rate of radiographic progression over 2 years compared to those receiving usual care (PMID: 24692365). The T2T group demonstrated a mean change in the Sharp/van der Heijde score of 0.6, indicating minimal progression, while the control group had a mean change of 2.4.
Additionally, a systematic review and meta-analysis of T2T strategies in early RA confirmed that patients managed with T2T achieved better clinical outcomes, including higher rates of remission and lower disease activity scores (PMID: 29370278). The analysis included data from multiple studies, reinforcing the robustness of T2T as an effective management strategy.
Despite these positive findings, the T2T approach requires regular monitoring of disease activity and may involve frequent adjustments in therapy, which can be resource-intensive. The choice of target (remission vs. low disease activity) may also vary based on patient preferences and clinical circumstances.
Caveats and uncertainty
While the evidence supporting T2T is compelling, there are several caveats to consider. First, most studies have focused on specific populations, which may limit the generalizability of findings to broader patient groups. For instance, the majority of trials included patients with early RA who were treatment-naïve, which may not reflect the complexities of managing patients with established disease or those with comorbidities.Additionally, the definition of "target" can vary among studies, with some focusing on remission while others emphasize low disease activity. This variability can complicate comparisons across studies and may influence clinical decision-making.
Moreover, the long-term sustainability of remission achieved through T2T strategies remains uncertain. While short-term benefits are well-documented, further research is needed to assess the durability of these outcomes over time and the potential need for ongoing adjustments in therapy.
How this may change practice
The T2T strategy is likely to influence clinical practice by promoting a more structured approach to managing early RA. Clinicians may increasingly adopt T2T protocols to optimize treatment outcomes, focusing on regular assessments of disease activity and timely adjustments in therapy.This shift towards a T2T approach may also enhance patient engagement, as individuals are more involved in their treatment goals and progress. Educating patients about the importance of achieving specific targets can improve adherence to therapy and overall satisfaction with care.
As the evidence base continues to grow, clinicians may refine their strategies for implementing T2T, including the use of validated disease activity measures and patient-reported outcomes. This evolution in practice could lead to improved long-term outcomes for patients with early RA.